BioNTech SE

BioNTech SE

BioNTech SE

Overview
Date Founded

2009

Headquarters

An der Goldgrube 12,Mainz, Rheinland-Pfalz 55131

Type of Company

Public

Employees (Worldwide)

1,941

Industries

Biotechnology
Hospitals & Patient Services
Industrial Machinery & Manufacturing
Retail: Other
Consumer Services
Medical Products & Equipment

Company Description

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Contact Data
Trying to get in touch with decision makers at BioNTech SE? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & Chief Executive Officer

Chief Financial Officer & Chief Operating Officer

Chief Business & Commercial Officer

Chief Medical Officer

Chief Strategy Officer & Managing Director

Co-Founder

Vice President, Investor Relations & Strategy

Vice President, Legal & IP

Supervisory Board

Co-Managing Director at AT Impf GmbH

Professional at Trilantic Capital Management LP

Co-Founder at BioNTech SE

Co-Founder at MIG Verwaltungs AG

Paths to BioNTech SE
Potential Connections via
Relationship Science
You
BioNTech SE
Owners & Shareholders
Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Dorsey, Wright & Associates' (DWA) investment approach is based on relative strength security analysis. They seek to build portfolios of strong relative strength stocks that will allow investors to participate in long-term performance trends.The firm offers two types of separately-managed accounts, Systematic Relative Strength accounts and Systematic RS SRI accounts. DWA's Systematic Relative Strength strategy employs a quantitative application of relative strength. The portfolio offers for four different objectives: Aggressive, Core, Balanced and International. They are fully invested at all times and all risk is managed through individual stock management and sector rotation. The firm's Systematic RS SRI is a socially responsible investment account that is managed through the application of DWA's Systematic Relative Strength methodology to a list of large-cap stocks that are screened by KLD Research & Analytics for environmental, social and governance characteristics.DWA also offers investments in two funds: the Arrow DWA Balanced Fund and the Arrow DWA Tactical Fund. The Arrow DWA Balanced Fund seeks to achieve an appropriate balance between long-term capital appreciation and capital preservation by investing in foreign and domestic equities, alternative assets and fixed-income. Dorsey Wright Money Management is the sub-advisor of the Fund. The Arrow DWA Tactical Fund seeks to achieve capital appreciation by tactically allocating assets primarily among ETFs. The Arrow DWA Tactical Fund provides similar advantages as the Arrow DWA Balanced Fund, but with fewer constraints in terms of exposure to various asset classes. Dorsey Wright Money Management is the sub-advisor of the fund. DWA uses technical analysis to allocate among four market segments: US equities, international equities, fixed-income and alternative assets.DWA also offers access to a mutual fund wrap program. The Rydex Dynamic Advantage Program is an asset allocation program that offers individual investors access to institutional money managers through 16 asset allocation strategies utilizing the Rydex family of mutual and variable trust funds. Dorsey Wright is the sub-advisor for 3 models available through DAP.

Details Hidden

PSV Fondsberatung GmbH is a private company headquartered in Pfaffenhofen, Germany. The firm provides investment advice. Jürgen Sarauer has been the CEO since 2019.

Recent Transactions
Details Hidden

BioNTech SE issued USD American Depositary Shares

Details Hidden

BioNTech SE purchases BioNTech US, Inc.

Details Hidden

BioNTech SE issued USD American Depositary Shares

Transaction Advisors
Legal Advisor

Advised onBioNTech SE issued USD American Depositary Shares

Underwriter

Advised onBioNTech SE issued USD American Depositary Shares

Underwriter

Advised onBioNTech SE issued USD American Depositary Shares

Managing Director Equities Healthcare

Advised onBioNTech SE issued USD American Depositary Shares

Managing Partner

Advised onBioNTech SE issued USD American Depositary Shares

Legal Advisor

Advised onBioNTech SE issued USD American Depositary Shares

Advisors & Consultants
Legal Advisor

Partner, New York at Cooley LLP

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Key Stats and Financials As of 2020
Market Capitalization
$42.5B
Total Enterprise Value
$19.1B
Earnings Per Share
$0.07
Total Equity
$1.68B
Total Debt
$294M
Net Profit
$17.3M
Revenue
$550M
Debt TEV
0.02x
TEVNet Income
1,100.88x
Enterprise Value / Sales
34.69x
EBITDAMargin
-47.24%
EBITDA
$-260M
Investors
Details Hidden

HEP seeks invests in fast-growing, market leading companies, operating in China, India, south korea and the ASEAN countries. The firm targets companies operating in the fields of financial services, healthcare, information technology, infrastructure, media, retail, telecommunications, consumer products, logistics and alternative energy. It provides financing for buyout and growth capital requirements with an investment size ranging from $10 to $50 million.

Details Hidden

ATS Beteiligungsverwaltung is an active manager which invests in selected German companies in the biotech sector.

Details Hidden

MIG is a private equity investment firm with a long-term outlook. The firm invests across sectors and development stages in innovative, generally medium-sized companies located primarily in Germany, Austria and Switzerland. Although they do not have sector restrictions, they favor technology-based companies and more particularly the biotechnology, healthcare and medical technology sectors. They aim to invest after thoroughly auditing the viability of potential investees, focusing on genuine innovation, high-growth market potential based on a clear customer benefit, and the entrepreneurial skills of the management team. They also look for companies with the potential to make a positive contribution to society.MIG describes their investment approach as that of a committed, entrepreneurial partner. The firm invests EUR 100 thousand and above in the form of direct equity, in startups and expansion-stage businesses. The firm may invest over several financing rounds, and investments are conditional on milestones being reached. MIG's targeted exit horizon is four to eight years.

Suppliers
Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines, as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory on the production line and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Genmab A/S Industrial Machinery & Manufacturing | Copenhagen, Denmark

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

4SC AG Pharmaceuticals | Planegg-martinsried, Deu

4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. Its product pipeline includes resminostat and domatinostat. The company was founded by Stefan Busemann, Ulrich Dauer, Klaus-Peter Gulden, and Daniel Vitt in 1997 and is headquartered in Planegg-Martinsried, Germany.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Moderna, Inc. Biotechnology - Cambridge, Massachusetts

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioNTech SE. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioNTech SE's profile does not indicate a business or promotional relationship of any kind between RelSci and BioNTech SE.